- Conditions
- Cardiovascular Disease, Hyperlipidemia
- Interventions
- Evolocumab, 18F-NaF PET, CCTA, Omnipaque, Metoprolol, Nitroglycerin
- Drug · Diagnostic Test
- Lead sponsor
- Cedars-Sinai Medical Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 55 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Los Angeles, California
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 70
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Coronary Artery Disease
- Interventions
- Evolocumab Injections
- Drug
- Lead sponsor
- Annapoorna Kini
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 137 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Primary Hypercholesterolemia, Mixed Dyslipidemia
- Interventions
- Evolocumab AMD, Evolocumab AI/pen
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 164 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2013
- U.S. locations
- 22
- States / cities
- Phoenix, Arizona • Encino, California • Thousand Oaks, California + 18 more
- Conditions
- Subjects With Hyperlipidemia, Dyslipidemia
- Interventions
- Evolocumab, Placebo
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 50 Years to 80 Years
- Enrollment
- 129 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 5
- States / cities
- Miami, Florida • Las Vegas, Nevada • Mooresville, North Carolina + 2 more
- Conditions
- Cardiovascular Disease, Myocardial Infarction, Stroke, Coronary Revascularization
- Interventions
- Evolocumab, Routine Lipid Management
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 6,019 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Fairhope, Alabama • Huntsville, Alabama + 73 more
- Conditions
- Lung Cancer Metastatic
- Interventions
- Nivolumab, Ipilimumab, Evolocumab
- Drug
- Lead sponsor
- Eziafa Oduah, MD, PhD, MPH
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 19 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2024
- U.S. locations
- 1
- States / cities
- Durham, North Carolina
- Conditions
- Dyslipidemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 5,035 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2022
- U.S. locations
- 144
- States / cities
- Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 136 more
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 99 Years
- Enrollment
- 770 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2018
- U.S. locations
- 24
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Long Beach, California + 21 more
- Conditions
- Critical Limb Ischemia
- Interventions
- Evolocumab 140mg/mL Injector 1milliliter (mL) Pen x 3 for a monthly dose of 420 mg for 12 months., Placebo 1 milliliter (mL) Injector Pen x 3 monthly for 12 months
- Drug · Other
- Lead sponsor
- Leonardo Clavijo
- Other
- Eligibility
- 40 Years to 85 Years
- Enrollment
- 32 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2022
- U.S. locations
- 1
- States / cities
- Los Angeles, California
- Conditions
- Hyperlipidemia, Mixed Dyslipidemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 18 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014
- U.S. locations
- 1
- States / cities
- Denver, Colorado
- Conditions
- Hyperlipidemias
- Interventions
- Evolocumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 18 Years to 85 Years
- Enrollment
- 81 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2025
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Hyperlipidemia
- Interventions
- Evolocumab, Ezetimibe, Placebo to Evolocumab, Placebo to Ezetimibe, Atorvastatin, Rosuvastatin, Simvastatin
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 80 Years
- Enrollment
- 2,067 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013
- U.S. locations
- 65
- States / cities
- Birmingham, Alabama • Glendale, Arizona • Tucson, Arizona + 58 more
- Conditions
- Type 2 Diabetes
- Interventions
- Statin, PCSK9 inhibitor, Ezetimibe 10mg
- Drug
- Lead sponsor
- NYU Langone Health
- Other
- Eligibility
- 18 Years to 89 Years
- Enrollment
- 151 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2020 – 2023
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Coronary Artery Disease
- Interventions
- statin, evolocumab
- Drug
- Lead sponsor
- Icahn School of Medicine at Mount Sinai
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 195 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2013 – 2022
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Familial Hypercholesterolemia
- Interventions
- Evolocumab
- Biological
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 10 Years to 17 Years
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2021
- U.S. locations
- 3
- States / cities
- The Bronx, New York • Cincinnati, Ohio • Nashville, Tennessee
- Conditions
- Hypercholesterolemia
- Interventions
- Evolocumab, Low-density Lipoprotein Cholesterol (LDL-C) Apheresis
- Biological · Procedure
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 39 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2017
- U.S. locations
- 4
- States / cities
- Boca Raton, Florida • Kansas City, Kansas • Grandville, Michigan + 1 more
- Conditions
- Hypercholesterolemia
- Interventions
- bempedoic acid 180mg, placebo, evolocumab
- Drug · Other
- Lead sponsor
- Esperion Therapeutics, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 59 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Louisville, Kentucky
- Conditions
- Healthy Participants, Pharmacokinetics
- Interventions
- Evolocumab Drug Substance A, Evolocumab Drug Substance B
- Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 405 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2026
- U.S. locations
- 4
- States / cities
- Springfield, Missouri • Columbus, Ohio • Dallas, Texas + 1 more
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- Evolocumab, Placebo
- Biological · Drug
- Lead sponsor
- Amgen
- Industry
- Eligibility
- 12 Years to 80 Years
- Enrollment
- 58 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2014
- U.S. locations
- 2
- States / cities
- New York, New York • Cincinnati, Ohio
- Conditions
- Stable Coronary Disease
- Interventions
- Evolocumab
- Drug
- Lead sponsor
- Brigham and Women's Hospital
- Other
- Eligibility
- 50 Years to 90 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2022 – 2027
- U.S. locations
- 1
- States / cities
- Boston, Massachusetts
- Conditions
- Melanoma
- Interventions
- Statins (atorvastatin, rosuvastatin, simvastatin, or pravastatin), +/- ezetimibe, +/- PCSK9 inhibitor (alirocumab, evolocumab, inclisiran)
- Drug
- Lead sponsor
- University of Colorado, Denver
- Other
- Eligibility
- 55 Years and older
- Enrollment
- 40 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2028
- U.S. locations
- 1
- States / cities
- Aurora, Colorado
- Conditions
- Dyslipidemias
- Interventions
- obicetrapib 10 mg + obicetrapib/evolocumab 140 mg Q 2 weeks
- Drug
- Lead sponsor
- NewAmsterdam Pharma
- Industry
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 69 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2024 – 2027
- U.S. locations
- 1
- States / cities
- Philadelphia, Pennsylvania
- Conditions
- Homozygous Familial Hypercholesterolemia
- Interventions
- lerodalcibep, evolocumab
- Drug
- Lead sponsor
- LIB Therapeutics LLC
- Industry
- Eligibility
- 10 Years and older
- Enrollment
- 65 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 2
- States / cities
- Evanston, Illinois • Cincinnati, Ohio
- Conditions
- Atherosclerotic Cardiovascular Disease, Familial Hypercholesterolemia
- Interventions
- Not listed
- Lead sponsor
- Novartis Pharmaceuticals
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 37,688 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2024
- U.S. locations
- 1
- States / cities
- East Hanover, New Jersey